Filtered By:
Cancer: Lung Cancer
This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 37398 results found since Jan 2013.
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer
CONCLUSIONS: ctDNA monitoring during induction chemoIO can inform treatment outcomes in patients with advanced NSCLC. Importantly, monitoring remains feasible and informative for patients missing baseline ctDNA. ctDNA testing during induction chemoIO identifies patients at higher risk for disease progression and may inform patient selection for novel personalized maintenance or second line treatment strategies.PMID:37702716 | DOI:10.1158/1078-0432.CCR-23-1578
Source: Clinical Cancer Research - September 13, 2023 Category: Cancer & Oncology Authors: Bruna Pellini Russell W Madison Merrida Childress Shoshana T Miller Ole Gjoerup Jason Cheng Richard S P Huang Michael Krainock Pratyush Gupta Wei Zou David S Shames Solomon Moshkevich Marcus Ballinger Minetta C Liu Amanda Young Minu K Srivastava Geoffrey Source Type: research
Randomized Open-Label Controlled Study of Cancer Vaccine OSE2101 Versus Chemotherapy in HLA-A2-positive Patients with Advanced Non-Small Cell Lung Cancer with Resistance to Immunotherapy: ATALANTE-1
CONCLUSION: In HLA-A2 positive patients with advanced NSCLC and secondary resistance to immunotherapy, OSE2101 increased survival with better safety compared to chemotherapy. Further evaluation in this population is warranted.PMID:37704166 | DOI:10.1016/j.annonc.2023.07.006
Source: Ann Oncol - September 13, 2023 Category: Cancer & Oncology Authors: B Besse E Felip R Garcia Campelo M Cobo C Mascaux A Madroszyk F Cappuzzo W Hilgers G Romano F Denis S Viteri D Debieuvre D Galetta E Baldini None M Razaq G Robinet M Maio A Delmonte B Roch P Masson W Schuette A Zer J Remon D Costantini B Vasseur R Dziadzi Source Type: research
Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer
CONCLUSIONS: Women were more likely to have HR+ NSCLC than men and EGFR and KRAS mutations occurred more commonly in HR+ NSCLC. Additional studies with more strict inclusion criteria for HR+ are warranted to see if there is benefit to targeting HR in these subgroups.PMID:37700839 | PMC:PMC10494442 | DOI:10.3389/fonc.2023.1215524
Source: Ann Oncol - September 13, 2023 Category: Cancer & Oncology Authors: Robert Hsu Denaly Chen Bing Xia Rebecca Feldman Wendy Cozen Luis E Raez Hossein Borghaei Chul Kim Misako Nagasaka Hirva Mamdani Ari M Vanderwalde Gilberto Lopes Mark A Socinski Antoinette J Wozniak Alexander I Spira Stephen V Liu Jorge J Nieva Source Type: research
Erratum: Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
J Clin Oncol. 2023 Sep 13:JCO2301849. doi: 10.1200/JCO.23.01849. Online ahead of print.NO ABSTRACTPMID:37703508 | DOI:10.1200/JCO.23.01849
Source: Clinical Lung Cancer - September 13, 2023 Category: Cancer & Oncology Source Type: research
Mesenteric Castleman Disease Misdiagnosed as Lymph Node Metastasis of Rectal Cancer on 18F-FDG PET/CT
Clin Nucl Med. 2023 Sep 7. doi: 10.1097/RLU.0000000000004832. Online ahead of print.ABSTRACTTwo years ago, a 64-year-old man underwent an 18F-FDG PET/CT for staging rectal cancer. Besides the hypermetabolic rectal lesion, the image revealed a mesenteric lymph node with intense activity and multiple lung nodules with slight FDG uptake, which were highly suspected of metastases. After surgery and multiple cycles of chemotherapy, the follow-up 18F-FDG PET/CT showed remission of all lesions except for the enlarged mesenteric lymph node with higher metabolic activity. Serum CEA remained normal during the follow-up. Postoperativ...
Source: Clinical Lung Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Meixi Liu Jiaolin Zhou Wenjia Zhu Li Huo Wuying Cheng Source Type: research
18F-FDG PET/CT Imaging of Pulmonary Hamartomas: Metabolic and Functional Characterization
We report the case of a 49-year-old woman recently diagnosed with left breast cancer with suspicious left axillary lymph nodes. 18F-FDG PET/CT showed well-circumscribed, lobulated, low-attenuation soft tissue mass in the right lower lobe lung with mild to no significant metabolic activity. CT-guided biopsy showed the lesion composed of fat, cartilage, and smooth muscle, admixed with fibroconnective tissue. The findings are consistent with pulmonary hamartoma. The presence of fat in a well-circumscribed solitary pulmonary nodule along with low metabolic activity helps in the characterization of the lesion, which can alter p...
Source: Clinical Lung Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Sharjeel Usmani Anjali Jain Syed M J Akhter Khulood Al Riyami Sofiullah Abubakar Asiya Al Busaidi Source Type: research
Clinico-pathological characteristics of IGFR1 and VEGF-A co-expression in early and locally advanced-stage lung adenocarcinoma
CONCLUSIONS: These results suggest that IGFR1+&VEGF-A+ is expected to be a disadvantageous factor for prognosis in the subgroup of EGFR mutation in patients with early and locally advanced-stage lung adenocarcinoma. What's more, this study may provide the theoretical possibility to screen optimal population for a combination therapy with anti-VEGF and anti-IGFR1 in patients with early and locally advanced-stage lung adenocarcinoma.PMID:37702808 | DOI:10.1007/s00432-023-05371-0
Source: Clinical Lung Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Wenting Liu Junling Xia Qingwu Du Jingya Wang Ting Mei Tingting Qin Source Type: research
Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders
CONCLUSIONS: Regional differences in mutations may exist with advanced stage accounting for prevalence of specific mutations. A national Trial Finder shows utility in finding targeted trials whilst commercial sequencing reports may over-report 'actionable' mutations. Understanding local prevalence and trial availability could increase enrolment onto matched early phase trials.PMID:37702806 | DOI:10.1007/s00432-023-05365-y
Source: Clinical Lung Cancer - September 13, 2023 Category: Cancer & Oncology Authors: S Rae E Plummer L Fitzgerald L Hogarth A Bridgewood L Brown-Schofield J Graham S Haigh C McAnulty Y Drew N Haris S Bashir R Plummer A Greystoke Source Type: research
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer
CONCLUSIONS: ctDNA monitoring during induction chemoIO can inform treatment outcomes in patients with advanced NSCLC. Importantly, monitoring remains feasible and informative for patients missing baseline ctDNA. ctDNA testing during induction chemoIO identifies patients at higher risk for disease progression and may inform patient selection for novel personalized maintenance or second line treatment strategies.PMID:37702716 | DOI:10.1158/1078-0432.CCR-23-1578
Source: Clinical Lung Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Bruna Pellini Russell W Madison Merrida Childress Shoshana T Miller Ole Gjoerup Jason Cheng Richard S P Huang Michael Krainock Pratyush Gupta Wei Zou David S Shames Solomon Moshkevich Marcus Ballinger Minetta C Liu Amanda Young Minu K Srivastava Geoffrey Source Type: research
The Prognostic and Functional Impact of Sprouty 2 Expression in Non-small Cell Lung Cancer
CONCLUSION: Spry2 expression was lower in tumor tissues than in normal lung parenchyma. Increased expression of Spry2 is associated with poor prognosis. There were no significant associations between epidermal growth factor receptor, anaplastic lymphoma kinase, or c-ros oncogene 1 rearrangement and Spry2 expression. Despite the absence of KRAS mutational analysis, the clinical and epidemiological features of patients suggested that KRAS mutation might be an underlying determinant factor of the functional role of Spry2 in non-small cell lung cancer.PMID:37700432 | DOI:10.1097/COC.0000000000001044
Source: Clinical Lung Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Yusuf Acikgoz Fatma Unal Yildirim Selin Akturk Esen Gokhan Ucar Yakup Ergun Oznur Bal Mutlu Dogan Dogan Uncu Source Type: research
Nicaraven Exerts a Limited Effect on Radiation-Induced Inhibition of Tumor Growth in a Subcutaneous Murine Tumor Model
Radiat Res. 2023 Sep 13. doi: 10.1667/RADE-22-00212.1. Online ahead of print.ABSTRACTNicaraven selectively protects normal tissue from radiation-induced injury. To further develop the clinical application of nicaraven for mitigating the side effects of cancer radiotherapy, we investigated the potential effect of nicaraven administration in radiation-induced inhibition of tumor growth. A subcutaneous tumor model was established in mice by the injection of Lewis lung cancer cells at the back of the chest. X-ray radiation was delivered to the thoracic area and different doses of nicaraven (0, 20, 50, 100 mg/kg) were administr...
Source: Cell Research - September 13, 2023 Category: Cytology Authors: Lina Abdelghany Yong Xu Reiko Sekiya Chen Yan Keiichi Jingu Tao-Sheng Li Source Type: research
Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain
CONCLUSION: The results of this study suggest that lorlatinib may be a dominant treatment option versus alectinib. Considering a willingness-to-pay threshold of €25,000/QALY, lorlatinib may be an efficient option compared to brigatinib.PMID:37701861 | PMC:PMC10494862 | DOI:10.2147/CEOR.S415711
Source: Cell Research - September 13, 2023 Category: Cytology Authors: Mar ía Presa David Vicente Antonio Calles Laura Salinas-Ortega Jaesh Naik Luis F Garc ía Javier Soto Source Type: research
Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib
CONCLUSION: Sotorasib and adagrasib demonstrated promising outcomes in targeting the constitutively active KRAS G12C oncogenic driver, underscoring the need for further research to optimize their therapeutic application in this high-risk population.PMID:37700573 | DOI:10.1177/10600280231197459
Source: The Annals of Pharmacotherapy - September 13, 2023 Category: Drugs & Pharmacology Authors: Natalie Mausey Zachery Halford Source Type: research
With Comparable Outcomes, Should Early Stage Lung Cancer Be A Contraindication to Lung Transplant?
CONCLUSIONS: One- and 5-year survival rates were comparable between LTx recipients with incidentally noted pathological Stage I NSCLC and contemporary recipients without cancer. All cancer-related mortality occurred in recipients with incidentally noted advanced NSCLC. These results suggest that patients with pathological Stage I lung cancer at the time of transplant have outcomes comparable to those without cancer findings at the time of transplant.PMID:37704001 | DOI:10.1016/j.athoracsur.2023.09.002
Source: The Annals of Thoracic Surgery - September 13, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Connor S Spies Timothy N Ochoa Arya Pontula Chelsea S Harris Laurie D Snyder Elizabeth N Pavlisko Matthew G Hartwig Source Type: research
Ugonin P inhibits lung cancer motility by suppressing DPP-4 expression via promoting the synthesis of miR-130b-5p
This study provides compelling evidence that ugonin P could be used to develop novel therapeutic agents for the treatment of lung cancer.PMID:37703658 | DOI:10.1016/j.biopha.2023.115483
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 13, 2023 Category: Drugs & Pharmacology Authors: Chih-Ying Wu Shubham Suresh Ghule Chih-Chuang Liaw David Achudhan Shuen-Yih Fang Po-I Liu Chang-Lun Huang Ching-Liang Hsieh Chih-Hsin Tang Source Type: research
